Prenatal exposition to haloperidol: A preclinical narrative review

Neurosci Biobehav Rev. 2023 Dec:155:105470. doi: 10.1016/j.neubiorev.2023.105470. Epub 2023 Nov 19.

Abstract

Pre-existing maternal mental disorders may affect the early interactions between mother and baby, impacting the child's psychoemotional development. The typical antipsychotic haloperidol can be used during pregnancy, even with some restrictions. Its prescription is not limited to psychotic disorders, but also to other psychiatric conditions of high incidence and prevalence in the woman's fertile period. The present review focused on the preclinical available data regarding the biological and behavioral implications of embryonic exposure to haloperidol. The understanding of the effects of psychotropic drugs during neurodevelopment is important for its clinical aspect since there is limited evidence regarding the risks of antipsychotic drug treatment in pregnant women and their children. Moreover, a better comprehension of the mechanistic events that can be affected by antipsychotic treatment during the critical period of neurodevelopment may offer insights into the pathophysiology of neurodevelopmental disorders. The findings presented in this review converge to the existence of several risks associated with prenatal exposure to such medication and emphasize the need for further studies regarding its dimensions.

Keywords: First-generation antipsychotics; Neurodevelopment; Offspring toxicity; Prenatal exposure.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Child
  • Female
  • Haloperidol / adverse effects
  • Humans
  • Neurodevelopmental Disorders*
  • Pregnancy
  • Prenatal Exposure Delayed Effects*
  • Psychotic Disorders* / drug therapy
  • Psychotic Disorders* / epidemiology
  • Psychotropic Drugs / therapeutic use

Substances

  • Haloperidol
  • Antipsychotic Agents
  • Psychotropic Drugs